New oral drug MRX-2843 tested in Hard-to-Treat leukemias
Disease control
Recruiting now
This early-stage trial is testing an experimental oral drug called MRX-2843 in adolescents and adults whose acute leukemia (AML, ALL, or mixed phenotype) has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and s…
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC